Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.83 |
| ▸ | BRAF | P15056 | 9/20 | 0.66 |
| ▸ | KDR | P35968 | 9/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844521 | 0.91 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL23201720 | 0.91 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL25641519 | 0.90 | MAPK14 (0.68) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL25921946 | 0.89 | MAPK14 (0.86) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL23201689 | 0.89 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL29844613 | 0.89 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL23201682 | 0.85 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL29844557 | 0.85 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL25917459 | 0.85 | MAPK14 (0.77) | MAPK14BRAFKDRMAPK13 | |
| SCHEMBL29844389 | 0.85 | MAPK14 (1.00) | MAPK14BRAFKDRMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885BRAF 50/4885KDR 3885/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885BRAF 50/4885KDR 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.